Media

Immuron (ASX:IMC) is another company working with US Department of Defence. It also serves as an example of how far a clinical candidate can go when a company works with the US Department of Defence for a number of years

Immuron has filed a pre-investigational new drug application with the United States Food and Drug Administration for IMM-529, designed as a new therapeutic to prevent and treat recurrent Clostridioides difficile infection

Immuron is in the throes of multiple clinical trials to prove the efficacy of Travelan against specific diarrhoea-inducing pathogens.

CEO Steve Lydeamore provides an update on Travelan's exponential growth!

The Not Old Better Show, Art of Living Interview Series. Today's episode takes us on a fascinating journey through the landscape of travel health, an essential yet often overlooked aspect of our adventures abroad.

Immuron Ltd (NASDAQ:IMRN, ASX:IMC), a biopharmaceutical company headquartered in Australia, says sales of its immune supplement Travelan® have soared.

Immuron CEO Steve Lydeamore speaks about the clinical work it is doing with IMM-124e and IMM-529, its involvement with the Uniformed Services University and the Naval Medical Research Command, and the commercial opportunity for Travelan.

We might like experiencing new places, but our tummies don’t always agree with us. Here’s something that might suit some. Travelan is an immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract.

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan®

Immuron Limited is commercializing and developing a novel class of specifically targeted polyclonal antibodies which are delivered within the gastrointestinal tract and do not cross into the bloodstream.

Host Jonathan Miller interviews CEO: Steven Lydeamore. He talks about the exponential growth on sales in the past year.

Planet MicroCap spoke with Steven Lydeamore, CEO of Immuron Ltd. (ASX: IMC) (NASDAQ: IMRN) via Zoom to discuss

Immuron Limited (ASX: IMC; NASDAQ: IMRN), the Melbourne-based biopharmaceutical firm, has reported a stellar performance for FY23 with a 136% surge in global sales compared to FY22.

The Board of Directors of Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has given the green light for the company to proceed with IMM-529 cGMP manufacturing for the treatment of a form of gastrointestinal disease.

Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steven Lydeamore is a numbers guy. You can tell by the thoughtful, considered way he reflects on his experience that a knack for numbers has informed his leadership style.

Immuron Ltd posted a revenue of $584,000 in H1 FY23, a growth of 153% compared to H1 FY22, with Australian sales contributing $287,000.

Immuron Limited CEO Steven Lydeamore interview with Stuart Roberts Management Interview Series – Stocks Down Under

Immuron (ASX:IMC) has updated on the US Department of Defense Uniformed Services University (USU) clinical evaluation of the company's Travelan.

Immuron Limited CEO Steven Lydeamore joined Steve Darling from Proactive to share news about the Australian Biotech company that is looking at using its technology for product development around gut health